French biotech Valneva has started manufacturing its vaccine candidate in Scotland, the U.K. government announced Thursday.

The move follows a multi-million-pound joint investment in the facility in Livingston, West Lothian, by the U.K. government in 2020 as part of an in-principle agreement to secure early access to Valneva’s first 60 million vaccine doses, with an option to acquire a further 130 million if the jab is approved.